BRUSSELS, Nov. 10 (Xinhua) -- The European Union (EU) will authorize a contract for the purchase of up to 300 million doses of the COVID-19 vaccine jointly developed by German company BioNTech and its American partner Pfizer, European Commission President Ursula von der Leyen said on Tuesday.
"This is the most promising vaccine so far," she said on Twitter. The contract, due to be reached on Wednesday, will be the fourth one the EU secures with a pharmaceutical company to buy vaccines for COVID-19.
The BioNTech/Pfizer vaccine candidate has proved to be more than 90 percent effective in preventing COVID-19 infection in participants with no proven previous SARS-CoV-2 infection, the two companies announced on Monday.
As the world is struggling to contain the COVID-19 pandemic, countries including Germany, China, Russia, the United Kingdom and the United States are racing to find a vaccine.
According to the website of the World Health Organization, as of Nov. 3, there were 202 COVID-19 candidate vaccines being developed worldwide, and 47 of them were in clinical trials.
Fire brigade in Shanghai holds group wedding
Tourists enjoy ice sculptures in Datan Town, north China
Sunset scenery of Dayan Pagoda in Xi'an
Tourists have fun at scenic spot in Nanlong Town, NW China
Harbin attracts tourists by making best use of ice in winter
In pics: FIS Alpine Ski Women's World Cup Slalom
Black-necked cranes rest at reservoir in Lhunzhub County, Lhasa
China's FAST telescope will be available to foreign scientists in April
"She power" plays indispensable role in poverty alleviation
Top 10 world news events of People's Daily in 2020
Top 10 China news events of People's Daily in 2020
Top 10 media buzzwords of 2020
Year-ender:10 major tourism stories of 2020
No interference in Venezuelan issues
Biz prepares for trade spat
Broadcasting Continent
Australia wins Chinese CEOs as US loses
